The long-term extension study found that intravenous golimumab for polyarticular-course juvenile idiopathic arthritis maintained a durable clinical response through 116 weeks. The drug’s pharmacokinetics and immunogenicity were consistent up to 244 weeks. The study, published in The Journal of Rheumatology, showed that golimumab generally reduced symptoms and was well-tolerated in patients with JIA. The researchers suggested that escalation of therapy is recommended for patients with continued active disease. Future studies could assess the proportion of patients achieving JIA inactive disease or JIA ACR100. The study was sponsored by Janssen Research and Development, LLC.
Source link
Intravenous golimumab shows long-term benefit for juvenile idiopathic arthritis
